Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Active, not recruiting · Phase 2 · NCT03198026
Conditions: Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
At a glance
- Research payments reported, 2025
- $967,584
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 29
About the trial
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (with Genentech, Inc., Pharmacyclics LLC.)
- Tested
- Ibrutinib (drug), Obinutuzumab (biological), Laboratory Biomarker Analysis (other)
- Dates
- Started 2018-02-20; completion 2032-02-20
- Results posted
- Yes
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.
From ClinicalTrials.gov, last updated 2026-08-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $967,584 in research payments for this study in 2025 (2 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Thomas Jefferson University Hospital $967,584
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.